TechNavio today launched its report Global Next-generation Cancer Diagnostic Devices Market 2012-2016 based on an in-depth analysis covering the Americas, and the EMEA and APAC regions. The report aims to aid decision makers’ understanding of the significant trends impacting this market.
Commenting on the report, an analyst from TechNavio’s Healthcare team said:”Recently, there has been a significant increase in medical tourism in the APAC region. In fact, India is currently the global hub for medical tourism. Many healthcare providers in the US and Europe recommend that patients visit APAC countries for medical consultations. Therefore, patients from across the globe are visiting countries in the APAC region, including India and China, for the diagnosis of cancer because of the advanced healthcare facilities and qualified healthcare providers available in these countries.”
According to the report, the increasing demand for biomarker-based tests is one of the major drivers in the Global Next-generation Cancer Diagnostic Devices market. Due to the continuous advancements in genomic research and the development of cost-effective biomarker-based tests, the demand for biomarker-based tests is increasing. Additionally, initiatives being taken by various governments across the globe to increase awareness of cancer are increasing the demand for biomarker-based tests, which is in turn fueling the growth of the Global Next-generation Cancer Diagnostic Devices Market.
Further, the report states that the low awareness about the availability of these devices is one of the major challenges in the Global Next-generation Cancer Diagnostic Devices market.
The report also includes a discussion of the key vendors operating in this market. The key vendors dominating this market space are Abbott Laboratories, Agilent Technologies Inc., Roche Holding Ltd., and Siemens Healthcare. The other vendors mentioned in the report are Beckman Coulter Inc., Johnson and Johnson, Becton Dickinson and Co., QIAGEN N.V., Thermo Fisher Scientific Inc., Affymetrix Inc., GE Healthcare, Life Technologies Corp., Luminex Corp., Illumina Inc., IRIS International Inc., Cepheid Inc., bioMerieux SA, Alere Inc., Allegro Diagnostics Corp., Fluidigm Corp., Nanosphere Inc., PerkinElmer Inc., Randox Laboratories Ltd., Oncolys BioPharma Inc., SomaLogic Inc., Radient Pharmaceuticals Corp., Quest Diagnostics Inc., Asuragen Inc., AVIVA Biosciences Corp., Veridex LLC, A. Menarini Diagnostics S.r.l., and Fujirebio Diagnostics Inc.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit https://www.technavio.com/content/global-next-generation-cancer-diagnosti…
TechNavio, the market research platform of Infiniti Research Ltd., publishes periodic market research reports on niche and emerging technologies. For more information on our Healthcare market research, please visit https://www.technavio.com/healthcare
Follow us on Twitter @ Technavio
TechNavio Announces the Publication of its Research Report – Global Next Generation Cancer Diagnostic Devices Market 2012-2016
